A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques
Ting Bian, Meng Hao, Xiaofan Zhao, Chuanyi Zhao, Gang Luo, Zhendong Zhang, Guangcheng Fu, Yang Lu, Yi Chen, Yudong Wang, Changming Yu, Yilong Yang, Jianmin Li, Wei Chen
Abstract
Abstract Rift Valley fever virus (RVFV) is listed as a priority pathogen by the World Health Organization (WHO) because it causes serious and fatal disease in humans, and there are currently no effective countermeasures. Therefore, it is urgent to develop a safe and efficacious vaccine. Here, we developed six nucleotide-modified mRNA vaccines encoding different regions of the Gn and Gc proteins of RVFV encapsulated in lipid nanoparticles, compared their ability to induce immune responses in mice and found that mRNA vaccine encoding the full-length Gn and Gc proteins had the strongest ability to induce cellular and humoral immune responses. IFNAR (−/−) mice vaccinated with mRNA-GnGc were protected from lethal RVFV challenge. In addition, mRNA-GnGc induced high levels of neutralizing antibodies and cellular responses in rhesus macaques, as well as antigen-specific memory B cells. These data demonstrated that mRNA-GnGc is a potent and promising vaccine candidate for RVFV.